Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.
KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism Jefferies’ new price target represents a potential upside of about 34% from the stock’s closing price on Friday.
Got $300? 2 Biotech Stocks to Buy and Hold Forever These two biotechs only have one marketable therapy each, but both have blockbuster potential.
Soleus Adds a Significant Number of Celcuity Shares This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment.
Why a Fund Placed a $13 Million Bet on Ambarella Stock Before a 20% Post-Earnings Drop The timing looks painful, but the fundamentals tell a more complicated story about why long-term investors are still paying attention.
Is IPG Photonics Stock a Buy as One Fund Builds a $9 Million Stake in the Firm? A sharp rebound in margins and profitability is testing whether patience can finally pay off for investors willing to look past years of volatility.
Why One Fund Has an $8.5 Million Bet on Five9 Despite a 50% One-Year Stock Collapse The stock’s collapse tells one story, but the underlying business metrics suggest a very different long-term setup.
Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock One fast-growing digital health stock just secured a notable new backer—right as its financial momentum hits a fresh gear.
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? One fund is quietly buying into ACADIA — just as the company posts one of its strongest quarters in years.
Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers and some providers, faced considerable downward pressure. This divergence highlights a sector grappling with a flurry of groundbreaking drug
Krystal Biotech (KRYS) Q3 2025 Earnings Top Estimates on Strong VYJUVEK Sales Krystal Biotech's Q3 2025 earnings crushed estimates, with EPS of $2.66 and $97.8M revenue. Strong VYJUVEK sales and global expansion in Europe and Japan drive growth.
